Immix Biopharma (NASDAQ:IMMX) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Immix Biopharma (NASDAQ:IMMX) issued its quarterly earnings results on Tuesday. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08), Zacks reports.

Immix Biopharma Stock Up 2.9 %

Shares of Immix Biopharma stock traded up $0.05 during trading hours on Thursday, reaching $1.62. 6,793 shares of the company’s stock were exchanged, compared to its average volume of 177,367. The business has a fifty day moving average of $1.66 and a two-hundred day moving average of $1.97. The company has a market capitalization of $44.33 million, a P/E ratio of -1.90 and a beta of 0.11. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $7.75.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Immix Biopharma in a research report on Thursday, October 3rd.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.